Evogene Q3 2023 Earnings Report

Evogene EPS Results

• Actual EPS: -$0.80
• Consensus EPS: -$1.70
• Beat/Miss: Beat by +$0.90
• One Year Ago EPS: -$1.60

Evogene Revenue Results

• Actual Revenue: $3.77 million
• Expected Revenue: $1.09 million
• Beat/Miss: Beat by +$2.68 million
• YoY Revenue Growth: N/A

Evogene Announcement Details

• Quarter: Q3 2023
• Date: 11/15/2023
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 15, 2023
• Conference Call Time: 9:00AM ET

Evogene (NASDAQ:EVGN) is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens. The company’s ag biotech pipeline encompasses both gene products and microbial strains, with programs targeting major crops such as corn, wheat and soybean. Simultaneously, Evogene is expanding into the human health arena through its microbiome business units, which aim to develop diagnostic tools and therapeutic candidates that leverage beneficial microorganisms to address gastrointestinal and metabolic disorders.

Evogene collaborates with leading global partners in the agrochemical and life sciences industries, licensing its computationally discovered assets for further development and commercialization. These partnerships extend across North America, Europe and Asia, supporting field trials and clinical studies. The company maintains an extensive intellectual property portfolio covering its platform technologies and product candidates. Evogene trades on the NASDAQ under the ticker symbol EVGN and continues to advance its pipeline through a combination of in-house research, strategic alliances and third-party collaborations.